Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 2Phase 1 2

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 4Gynecologic 3Thoracic 2Lymphoid 2Head & Neck 2Genitourinary 2Dermatologic 2Breast 2Other solid neoplasm 1

Conditions

Melanoma 777Carcinoma, Non-Small-Cell Lung 198Lymphoma, T-Cell, Cutaneous 171Carcinoma, Renal Cell 139Neoplasms 130Mycosis Fungoides 120Breast Neoplasms 114Lymphoma, Large B-Cell, Diffuse 112Colorectal Neoplasms 111Lymphoma, Non-Hodgkin 110Sezary Syndrome 109Lymphoma, Follicular 107Neoplasm Metastasis 105Lymphoma 103Leukemia, Lymphocytic, Chronic, B-Cell 103Lymphoma, Mantle-Cell 100Lymphoma, B-Cell, Marginal Zone 98Hodgkin Disease 98Precursor Cell Lymphoblastic Leukemia-Lymphoma 97Burkitt Lymphoma 94Squamous Cell Carcinoma of Head and Neck 92Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 92Lymphoma, Large-Cell, Immunoblastic 86Lymphoma, Large-Cell, Anaplastic 86Ovarian Neoplasms 84Lung Neoplasms 80Immunoblastic Lymphadenopathy 79Sarcoma 67Pancreatic Neoplasms 65Head and Neck Neoplasms 64

Interventions

pembrolizumab 1fludarabine 1atezolizumab 1aldesleukin 1Nivolumab 1Interleukin-2 1Cyclophosphamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Microsatellite Instability × Dermatologic × Clear all
NCT03841110 2023-05-01

FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors

Fate Therapeutics

Phase 1 Completed
37 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidThoracic

Breast Neoplasms, Carcinoma, Renal Cell, Carcinoma, Squamous Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Lymphoma, Melanoma, Pancreatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Microsatellite Instability, Small Cell Lung Carcinoma

NCT03538028 2020-10-30

A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies

Incyte Corporation

Phase 1 Completed
22 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidOther solid neoplasmThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Carcinoma, Hepatocellular, Melanoma, Mesothelioma, Neoplasm Metastasis, Ovarian Neoplasms, Recurrence, Stomach Neoplasms, Carcinoma, Merkel Cell, Lymphoma, Large B-Cell, Diffuse, Microsatellite Instability, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡